Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada
Current Oncology · 2024
DOI: 10.3390/curroncol31060251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Quincy Chu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd..
Abstract (Originalsprache)
This epidemiological model forecasted reductions in recurrences and recurrence treatment cost savings with adjuvant atezolizumab vs best supportive care among Canadians with stage II-IIIA non-small cell lung cancer (NSCLC) at national and provincial levels. The population had resected, programmed cell death 1 ligand 1 (PD-L1)–high (≥50%), EGFR−, ALK−, stage II-IIIA NSCLC eligible for adjuvant treatment. Patients with recurrence or death and the costs of treating recurrences were estimated for those receiving adjuvant atezolizumab or best supportive care each year (2024–2034). Proportions of patients expected to be event free up to 10 years after treatment initiation were extrapolated with parametric survival analyses. In the base case analysis, 240 fewer recurrences were estimated to occur over 10 years (2024–2034) with adjuvant atezolizumab vs best supportive care across Canada, with 136 (57%) and 104 (43%) fewer locoregional and metastatic recurrences, respectively. Projected costs of treated recurrences were CAD 33.2 million less over 10 years with adjuvant atezolizumab at a national level (adjuvant atezolizumab, CAD 135.8 million; best supportive care, CAD 169.0 million). This model predicts a considerable long-term reduction in recurrences and substantial treatment cost savings with adjuvant atezolizumab vs best supportive care for patients with PD-L1–high early-stage NSCLC in Canada.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
- Hoffmann-La Roche, Mississauga, ON L5N 5M8, Canada.
- F. Hoffmann-La Roche Ltd., 4052 Basel, Switzerland.
ORCID-Profile: Sarah Vaselenak, Melina Arnold
Förderung
- F. Hoffmann-La Roche Ltd
- F. Hoffmann-La Roche Ltd.
Zitieren
APA
Chu, Q., Sripada, K., Vaselenak, S., Jovanoski, N., & Arnold, M. (2024). Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada. Current Oncology. https://doi.org/10.3390/curroncol31060251
Vancouver
Chu Q, Sripada K, Vaselenak S, Jovanoski N, Arnold M. Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada. Current Oncology. 2024. doi:10.3390/curroncol31060251
BibTeX
@article{Chu2024,
author = {Chu, Quincy and Sripada, Kaushik and Vaselenak, Sarah and Jovanoski, Nick and Arnold, Melina},
title = {Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31060251}
}
EUVIMED